ロード中...
11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
BACKGROUND: Continued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is unknown if 11KT is present at physiologically relevant concent...
保存先:
| 出版年: | JCI Insight |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Clinical Investigation
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262344/ https://ncbi.nlm.nih.gov/pubmed/33974560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.148507 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|